Cogent Biosciences (COGT) Other Operating Expenses (2019 - 2020)
Cogent Biosciences (COGT) posted quarterly Other Operating Expenses of $23000.0 for Q4 2020, up 675.0% year-over-year from $2967.7 in Q1 2020, and down 99.69% quarter-over-quarter from $7.5 million in Q3 2020.
Powered by 
Analysis
Cogent Biosciences (COGT) Other Operating Expenses (2019 - 2020) Analysis & Trends
Cogent Biosciences (COGT) has reported Other Operating Expenses for 2 consecutive years, with $23000.0 the latest figure, recorded in Q4 2020.
- In Q4 2020, Other Operating Expenses rose 675.0% year-over-year to $23000.0; the TTM figure through Sep 2021 stood at $23000.0 (down 99.69% YoY), while the FY2020 annual figure was $7.5 million, up 9506.41% from the prior year.
- Other Operating Expenses eased to $23000.0 in Q4 2020 per COGT's latest filing, from $7.5 million in the prior quarter.
- Across five years, Other Operating Expenses topped out at $7.5 million in Q3 2020 and bottomed at -$4000.0 in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 10 | Cogent Biosciences | 5.95 Bn | 5.95 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2020 | 23,000.00 |
| Sep 30, 2020 | 7.46 Mn |
| Dec 31, 2019 | -4,000.00 |
| Sep 30, 2019 | 82,000.00 |